About Veristat
Veristat is a Healthcare company based in Chatham (United States) founded in 2003 by Kyle McBride, Mark McBride, and Dave Koster, and was acquired by Veristat in October 2023. Veristat is engaged in providing clinical research and consultancy services. It operates on a Professional Services and Managed Services model. Its chief executive, as recorded, is Kyle McBride. Its Indian entity Instat Clinical Research Private Limited reported revenue of ₹7.32 Cr. Veristat offers products and services including Full-Service Clinical Trials, Biometrics, and Regulatory Affairs. Its focus areas include Biotechnology and Clinical Research. Its competitors include Medpace, JCCT and Ascada Research.
Company details
Veristat is involved in delivering full-service clinical research solutions and consultancy across the entire lifecycle of therapeutic development. Services are offered in areas such as clinical trial planning, regulatory submissions, and commercialization. Specialized solutions are provided for biologics, rare diseases, and decentralized trials. Expertise is extended to therapeutic areas including oncology, neurology, and infectious diseases. Comprehensive support is given through biometrics, medical writing, and pharmacovigilance to ensure regulatory compliance and patient safety.
- Headquarters Chatham, United States
- Founders Kyle McBride, Mark McBride, Dave Koster
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website instat.com
- Social LinkedIn X Facebook YouTube
- Acquired by Veristat (Oct 2023)
- Legal Name Veristat, Llc
- Date of Incorporation 27 Oct, 2015
- Jurisdiction Kanchipuram, Tamil Nadu, India
Associated legal entities of Veristat
Veristat operates through Instat Clinical Research Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Instat Clinical Research Private Limited CIN U72900TN2015PTC102702 | Active | 27 Oct 2015 | Kanchipuram, Tamil Nadu | ₹7.3 Cr | 28 | 3 | View details |
Products & Services of Veristat
Veristat offers a comprehensive portfolio of products and services, including Full-Service Clinical Trials, Biometrics, and Regulatory Affairs.
Clinical trials are managed through all development phases.
Clinical trial data is collected, analyzed, and reported.
Regulatory expertise is provided for clinical development phases.
Apps and channels of Veristat
its YouTube channel Veristat has 208 subscribers and 30 videos.
Videos from Veristat
The most watched videos on Veristat's YouTube channel, Veristat (208 subscribers). Click a video to play it here.
More on Veristat.
Investors in Veristat
Veristat has secured backing from 1 investor. Prominent investors backing the company include Veristat.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Clinical trials and regulatory submissions are supported as a CRO. | 1994 | veristat.com | Southborough, United States |
Investor details for Veristat
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Instat Clinical Research Private Limited (Veristat)
Instat Clinical Research Private Limited is the primary company behind Veristat. The board of Instat Clinical Research Private Limited currently have 3 directors; the longest-serving is Anitha Suresh, appointed in 2015. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anitha Suresh DIN 07312194 | Director | 27 Oct 2015 | 11 yrs | Instat Clinical Research Private Limited |
| Cynthia Marie Henderson DIN 10342773 | Additional Director | 16 Oct 2023 | 3 yrs | Instat Clinical Research Private Limited |
| Patrick Thomas Flanagan DIN 10342775 | Additional Director | 16 Oct 2023 | 3 yrs | Instat Clinical Research Private Limited |
People of Veristat
3 people are tracked at Veristat (3 in leadership).
| Name | Role | Group |
|---|---|---|
| Co-Founder & Co-CEO | Leadership | |
| Co-Founder & Co-CEO | Leadership | |
Dave Koster | Co-Founder & Co-CEO | Leadership |
Complete people profiles for Veristat
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Veristat
Figures of Instat Clinical Research Private Limited, the primary company behind Veristat, for FY 2024. Revenue was ₹7.32 Cr (+133% year on year). Net profit was ₹73.1 Lakh (10% margin). EBITDA was ₹1.03 Cr (14% margin). Revenue has grown at a compounded annual rate of +69% over three years and +16% over five years.
- ₹7.32 CrRevenue · FY 2024 · +133% YoY
- ₹73.1 LakhNet profit · 10% margin
- ₹1.03 CrEBITDA · 14% margin
- ₹2 LakhPaid-up capital
- 28Employees (provident fund records)
- +69%Revenue CAGR, 3 years
- +16%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Instat Clinical Research Private Limited are on its company page.
Detailed financial statements for Veristat
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Veristat
2 dated milestones of Veristat across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Veristat is founded.
- Exit Acquired by Veristat.
Competitors of Veristat
Veristat has 3 listed competitors in our database. They include Medpace, JCCT and Ascada Research.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medpace.com | 1992 | Cincinnati, United States | A range of clinical research services is offered by Medpace. | |||
| jcct.com | 2005 | Lenexa, United States | CRO focused on early & end stage clinical trial services | |||
| ascadaresearch.org | 2021 | Fullerton, United States | 31 | Performs clinical research trials to evaluate investigational drugs and devices. |
Detailed competitors of Veristat
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Veristat
Websites that share an audience with Veristat (instat.com).
Websites whose visitors overlap most with Veristat. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
instatfootball.com | instatfootball.com | 100% | #6,053,124 | – | |
| idc.com | 47% | 413.5K | #133,168 | View details | |
| reedbusiness.com | 45% | View details | |||
| yankeegroup.com | 34% | 9.7K | #2,143,121 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Veristat (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Veristat
Complete news archive for Veristat
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Veristat
Veristat was founded in 2003.
Veristat is headquartered in Chatham, United States.
Kyle McBride is the CEO of Veristat, as recorded in our data. They have also founded this company.
The primary company behind Veristat, Instat Clinical Research Private Limited, reported revenue of ₹7.32 Cr for FY 2024, up 133% year on year.
Veristat is involved in delivering full-service clinical research solutions and consultancy across the entire lifecycle of therapeutic development. Services are offered in areas such as clinical trial planning, regulatory submissions, and commercialization. Specialized solutions are provided for biologics, rare diseases, and decentralized trials. Expertise is extended to therapeutic areas including oncology, neurology, and infectious diseases. Comprehensive support is given through biometrics, medical writing, and pharmacovigilance to ensure regulatory compliance and patient safety.
Veristat's top competitors include Medpace, JCCT and Ascada Research.
Veristat offers Full-Service Clinical Trials, Biometrics, and Regulatory Affairs.
Veristat has 1 investor. Key investors include Veristat.
Veristat operates through Instat Clinical Research Private Limited.
Yes. Veristat was acquired by Veristat in October 2023.
The legal entities of Veristat currently have 3 directors, including Cynthia Marie Henderson, Patrick Thomas Flanagan, Anitha Suresh.